CoChat

Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells

Open access
Jia, Yannan, Han, Lina, Ramage, Cassandra L., Wang, Zhe, Weng, Connie C., Yang, Lei, Colla, Simona, Ma, Helen, Zhang, Weiguo, Andreeff, Michael, Daver, Naval, Jain, Nitin, Pemmaraju, Naveen, Bhalla, Kapil, Mustjoki, Satu, Zhang, Peiyi, Zheng, Guangrong, Zhou, Daohong, Zhang, Qi, Konopleva, Marina · 2023 · Haematologica
Cited by 74

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

BCL-XL and BCL-2 are key anti-apoptotic proteins and validated cancer targets. 753B is a novel BCL-XL/BCL-2 proteolysis targeting chimera (PROTAC) that targets both BCL-XL and BCL-2 to the von Hippel-Lindau (VHL) E3 ligase, leading to BCLX L/BCL-2 ubiquitination and degradation selectively in cells expressing VHL. Because platelets lack VHL expression, 753B spares on-target platelet toxicity caused by the first-generation dual BCL-XL/BCL-2 inhibitor navitoclax (ABT-263). Here, we report pre-clinical single-agent activity of 753B against different leukemia subsets. 753B effectively reduced cell viability and induced dose-dependent degradation of BCL-XL and BCL-2 in a subset of hematopoietic cell lines, acute myeloid leukemia (AML) primary samples, and in vivo patient-derived xenograft AML models. We further demonstrated the senolytic activity of 753B, which enhanced the efficacy of chemotherapy by targeting chemotherapy-induced cellular senescence. These results provide a pre-clinical rationale for the utility of 753B in AML therapy, and suggest that 753B could produce an added therapeutic benefit by overcoming cellular senescence-induced chemoresistance when combined with chemotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3324/haematol.2022.281915

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 74

Metadata

Authors
Jia, Y., Han, L., Ramage, C. L., Wang, Z., Weng, C. C., Yang, L., Colla, S., Ma, H., Zhang, W., Andreeff, M., Daver, N., Jain, N., Pemmaraju, N., Bhalla, K., Mustjoki, S., Zhang, P., Zheng, G., Zhou, D., Zhang, Q., & Konopleva, M.
Venue
Haematologica
Published
2023-04-20
Volume
108
Issue
10
Pages
2626-2638
ISSN
  • 0390-6078 (ISSN-L)
  • 1592-8721
OpenAlex
W4366463488
Cited by
74
References
19
FWCI
5.53
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells. https://app.cochat.ai/papers/10.3324/haematol.2022.281915
The paper
Jia, Y., Han, L., Ramage, C. L., Wang, Z., Weng, C. C., Yang, L., Colla, S., Ma, H., Zhang, W., Andreeff, M., Daver, N., Jain, N., Pemmaraju, N., Bhalla, K., Mustjoki, S., Zhang, P., Zheng, G., Zhou, D., Zhang, Q., & Konopleva, M. (2023). Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells. Haematologica. https://doi.org/10.3324/haematol.2022.281915

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.